NEW YORK, Dec. 6 (GenomeWeb News) - Shares in CombiMatrix were up $.07, or 4 percent, at $1.90 in mid-day trading after the company said it plans to offer a DNA-based microarray service to identify types of influenza.
The array will enable researchers to genetically identify influenza types, including the H5N1 bird flu. The company said the test can be run on both animal and human samples.
CombiMatrix Molecular Diagnostics, a wholly owned subsidiary of CombiMatrix formed in May, will offer the analysis for research purposes because the array is not an FDA approved product.
The Influenza microarray, part of CombiMatrix's CatalogArray product line, can detect and accurately type flu strains such as the H5N1 bird flu, as well as provide information on mutations and novel strains of flu not yet seen, the company said.